cabergoline has been researched along with Parkinson Disease, Secondary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuoka, S; Kawahara, S; Kimoto, N; Ogawa, N; Tanaka, K | 1 |
| Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E | 1 |
| Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N | 1 |
| Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E | 1 |
| Fukuda, T; Iwata, SI; Kaseda, S; Kita, S; Nomoto, M | 1 |
| Ahlskog, JE; Limper, AH; Ling, LH; Munger, TM; Oh, JK | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 1 |
7 other study(ies) available for cabergoline and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Effect of cabergoline on increase of several ER stress-related molecules in 6-OHDA-lesioned mice.
Topics: Animals; Antiparkinson Agents; Cabergoline; Caspase 12; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Ergolines; Male; Mice; Mice, Inbred ICR; Oligopeptides; Oxidopamine; Parkinson Disease, Secondary; Substantia Nigra; Transcription Factor CHOP | 2013 |
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide | 1995 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Striatum; Denervation; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Ergolines; Female; Gene Expression Regulation; Genes, fos; Haloperidol; Indoles; Macaca fascicularis; Male; Molecular Weight; MPTP Poisoning; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Phenanthridines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, Dopamine D1; RNA, Messenger; Species Specificity; Time Factors; Transcription Factors | 1996 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary | 1996 |
Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cabergoline; Callithrix; Dopamine Agents; Dopamine Agonists; Ergolines; Female; Male; Motor Activity; Parkinson Disease, Secondary | 1998 |
Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Lung Diseases; Male; Parkinson Disease, Secondary; Pericarditis, Constrictive; Pleural Diseases; Tomography, X-Ray Computed | 1999 |
125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Benzazepines; Benzoates; Binding Sites; Brain; Cabergoline; Corpus Striatum; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Ergolines; Female; GABA Antagonists; GABA-B Receptor Antagonists; Injections, Subcutaneous; Iodine Radioisotopes; Macaca fascicularis; Organophosphorus Compounds; Parkinson Disease, Secondary; Receptors, GABA-B; Substantia Nigra; Thalamus | 2000 |